+ Follow DR. HAL BARRON Tag
Array
(
[results] => Array
(
[0] => Array
(
[ArticleID] => 1243290
[Title] => New drug helps people with advanced HER2-positive breast cancer live longer
[Summary] => Roche announced recently that trastuzumab emtansine significantly extended the time people with advanced HER2-positive breast cancer (metastatic and unresectable locally advanced/recurrent) lived without their disease worsening (progression-free survival), compared to people who received a treatment of their physician’s choice in an open-label phase III study called TH3RESA.
[DatePublished] => 2013-10-10 00:00:00
[ColumnID] => 0
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
[1] => Array
(
[ArticleID] => 731565
[Title] => Treatment for advanced ovarian cancer receives positive opinion
[Summary] => BASEL, Switzerland — Roche has announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for the use of bevacizumab in combination with standard chemotherapy (carboplatin and paclitaxel) as a front-line treatment for women with advanced ovarian cancer.
[DatePublished] => 2011-09-29 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
[2] => Array
(
[ArticleID] => 703067
[Title] => Roche's drug receives broader EU label for women with metastatic breast cancer
[Summary] => BASEL, Switzerland — Roche announced this week that the European Commission (EC) has extended the existing bevacizumab metastatic breast cancer label to include combination with capecitabine.
[DatePublished] => 2011-07-07 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
[3] => Array
(
[ArticleID] => 696213
[Title] => Roche drug halves risk of disease worsening in women with recurrent ovarian cancer
[Summary] => Roche recently announced the results from OCEANS, a phase III study evaluating bevacizumab in combination with chemotherapy (gemcitabine and carboplatin) followed by the continued use of bevacizumab alone in women with previously treated (recurrent) platinum-sensitive ovarian cancer.
[DatePublished] => 2011-06-16 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
[4] => Array
(
[ArticleID] => 691717
[Title] => Roche announces new study data on rheumatoid arthritis treatment
[Summary] => Roche recently announced new data from the ACT-RAY study, presented at the European League Against Rheumatism congress.
[DatePublished] => 2011-06-02 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
[5] => Array
(
[ArticleID] => 689458
[Title] => Roche bares study results on lung cancer medicine
[Summary] => Roche announced this week the final results from a randomized, multi-center, double-blind Phase II study with its investigational personalized medicine, MetMAb, in people with previously treated advanced non-small cell lung cancer (NSCLC).
[DatePublished] => 2011-05-26 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
[6] => Array
(
[ArticleID] => 682217
[Title] => Roche drug for treating systemic juvenile idiopathic arthritis gets US FDA approval
[Summary] => The United States Food and Drug Administration (FDA) has approved Roche’s drug tocilizumab for the treatment of active systemic juvenile idiopathic arthritis (SJIA) in patients aged two and older.
[DatePublished] => 2011-05-05 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
[7] => Array
(
[ArticleID] => 678152
[Title] => Roche bares positive results of breast cancer drug
[Summary] => BASEL, Switzerland — Roche has announced the topline results of its first randomized trial of trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer.
[DatePublished] => 2011-04-21 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
[8] => Array
(
[ArticleID] => 671055
[Title] => Roche announces positive results for severe skin cancer medicine
[Summary] => BASEL, Switzerland — Roche announced this week that a pivotal Phase II clinical study of its investigational Hedgehog Pathway Inhibitor, vismodegib, showed positive results in people with advanced basal cell carcinoma (aBCC), a particularly severe and debilitating form of skin cancer.
[DatePublished] => 2011-03-31 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
[9] => Array
(
[ArticleID] => 657719
[Title] => Treatment helps women with ovarian cancer live significantly longer
[Summary] => Roche announced this week that OCEANS, a phase III study evaluating bevacizumab in combination with chemotherapy (carboplatin and gemcitabine) followed by continued use of bevacizumab alone until disease progression in women with previously treated (recurrent), platinum-sensitive ovarian cancer, met its primary endpoint.
[DatePublished] => 2011-02-17 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
)
)
DR. HAL BARRON
Array
(
[results] => Array
(
[0] => Array
(
[ArticleID] => 1243290
[Title] => New drug helps people with advanced HER2-positive breast cancer live longer
[Summary] => Roche announced recently that trastuzumab emtansine significantly extended the time people with advanced HER2-positive breast cancer (metastatic and unresectable locally advanced/recurrent) lived without their disease worsening (progression-free survival), compared to people who received a treatment of their physician’s choice in an open-label phase III study called TH3RESA.
[DatePublished] => 2013-10-10 00:00:00
[ColumnID] => 0
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
[1] => Array
(
[ArticleID] => 731565
[Title] => Treatment for advanced ovarian cancer receives positive opinion
[Summary] => BASEL, Switzerland — Roche has announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for the use of bevacizumab in combination with standard chemotherapy (carboplatin and paclitaxel) as a front-line treatment for women with advanced ovarian cancer.
[DatePublished] => 2011-09-29 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
[2] => Array
(
[ArticleID] => 703067
[Title] => Roche's drug receives broader EU label for women with metastatic breast cancer
[Summary] => BASEL, Switzerland — Roche announced this week that the European Commission (EC) has extended the existing bevacizumab metastatic breast cancer label to include combination with capecitabine.
[DatePublished] => 2011-07-07 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
[3] => Array
(
[ArticleID] => 696213
[Title] => Roche drug halves risk of disease worsening in women with recurrent ovarian cancer
[Summary] => Roche recently announced the results from OCEANS, a phase III study evaluating bevacizumab in combination with chemotherapy (gemcitabine and carboplatin) followed by the continued use of bevacizumab alone in women with previously treated (recurrent) platinum-sensitive ovarian cancer.
[DatePublished] => 2011-06-16 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
[4] => Array
(
[ArticleID] => 691717
[Title] => Roche announces new study data on rheumatoid arthritis treatment
[Summary] => Roche recently announced new data from the ACT-RAY study, presented at the European League Against Rheumatism congress.
[DatePublished] => 2011-06-02 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
[5] => Array
(
[ArticleID] => 689458
[Title] => Roche bares study results on lung cancer medicine
[Summary] => Roche announced this week the final results from a randomized, multi-center, double-blind Phase II study with its investigational personalized medicine, MetMAb, in people with previously treated advanced non-small cell lung cancer (NSCLC).
[DatePublished] => 2011-05-26 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
[6] => Array
(
[ArticleID] => 682217
[Title] => Roche drug for treating systemic juvenile idiopathic arthritis gets US FDA approval
[Summary] => The United States Food and Drug Administration (FDA) has approved Roche’s drug tocilizumab for the treatment of active systemic juvenile idiopathic arthritis (SJIA) in patients aged two and older.
[DatePublished] => 2011-05-05 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
[7] => Array
(
[ArticleID] => 678152
[Title] => Roche bares positive results of breast cancer drug
[Summary] => BASEL, Switzerland — Roche has announced the topline results of its first randomized trial of trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer.
[DatePublished] => 2011-04-21 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
[8] => Array
(
[ArticleID] => 671055
[Title] => Roche announces positive results for severe skin cancer medicine
[Summary] => BASEL, Switzerland — Roche announced this week that a pivotal Phase II clinical study of its investigational Hedgehog Pathway Inhibitor, vismodegib, showed positive results in people with advanced basal cell carcinoma (aBCC), a particularly severe and debilitating form of skin cancer.
[DatePublished] => 2011-03-31 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
[9] => Array
(
[ArticleID] => 657719
[Title] => Treatment helps women with ovarian cancer live significantly longer
[Summary] => Roche announced this week that OCEANS, a phase III study evaluating bevacizumab in combination with chemotherapy (carboplatin and gemcitabine) followed by continued use of bevacizumab alone until disease progression in women with previously treated (recurrent), platinum-sensitive ovarian cancer, met its primary endpoint.
[DatePublished] => 2011-02-17 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
)
)
abtest
October 10, 2013 - 12:00am
September 29, 2011 - 12:00am
February 17, 2011 - 12:00am